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INTRODUCTION 
The combined loss of both skeletal muscle mass 
(sarcopenia: [1]) and strength (dynapenia: [2–4]) in 
ageing, not only impairs locomotory function, impacting 
independence and quality of life, but can also 
compromise metabolic health. Reflecting this, there are 
robust epidemiological relationships between both 
sarcopenia and dynapenia, risk of non-communicable 
diseases (e.g. diabetes, COPD, cancer) and subsequent 
morbidity  and   mortality  [5–10].  Identifying  biological  
signatures associated with muscle ageing status is a 
potential approach to triage those in need of early 
intervention, develop tools for stratification or reveal 
targets for therapeutic manipulation [11–13]. 
In recent years there has been increased use of OMICs-
technologies (e.g. transcriptomics, proteomics and 
metabolomics) to examine the underlying aetiology of 
disease states and develop biomarkers for diagnosis or 
prognosis [14–16]. Metabolomic approaches, for 
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ABSTRACT 
Ageing compromises skeletal muscle mass and function through poorly defined molecular aetiology. Here we 
have used untargeted metabolomics using UHPLC-MS to profile muscle tissue from young (n=10, 25±4y), middle 
aged (n=18, 50±4y) and older (n=18, 70±3y) men and women (50:50). Random Forest was used to prioritise 
metabolite features most informative in stratifying older age, with potential biological context examined using 
the prize-collecting Steiner forest algorithm embedded in the PIUMet software, to identify metabolic pathways 
likely perturbed in ageing. This approach was able to filter a large dataset of several thousand metabolites 
down to subnetworks of age important metabolites. Identified networks included the common age-associated 
metabolites such as androgens, (poly)amines/amino acids and lipid metabolites, in addition to some potentially 
novel ageing related markers such as dihydrothymine and imidazolone-5-proprionic acid. The present study 
reveals that this approach is a potentially useful tool to identify processes underlying human tissue ageing, and 
could therefore be utilised in future studies to investigate the links between age predictive metabolites and 
common biomarkers linked to health and disease across age. 
www.aging-us.com 2 AGING 
instance, have already yielded insight into changes in 
the muscle metabolome with age. Fazelzadeh and 
colleagues recently used a targeted approach to 
investigate age-related changes in the muscle meta-
bolome and highlighted that metabolites associated with 
mitochondrial function, fibre type and tissue turnover 
all differed between age groups [17], in-keeping with 
established ageing physiology [18–20]. Johnson and 
colleagues examined the relationship between 
metabolites and indicators of health span, and 
demonstrated that blood concentrations of certain amino 
acids and lipids were associated with health-span 
indicators in ageing [21]. What is still not known, is 
whether changes in the skeletal muscle metabolome 
associated with ageing could be informative of an 
ageing tissue phenotype and link to other clinical 
health-related parameters. However one of the major 
issues in metabolomics is determining the most optimal 
approach for identification of these “biologically 
important” changes in the metabolome associated with 
ageing, so that these links to clinical/health outcomes 
can be determined and investigated further. 
 
Untargeted metabolomics datasets are notoriously 
difficult to analyse. Firstly, there is the ‘curse of 
dimensionality’ whereby the number of observed 
variables is much larger than the number of samples used 
to observe those variables. This leads to a large false 
positive rate using significance based statistical 
approaches. Secondly the ‘dark matter’ of untargeted 
metabolomics datasets means that physiologically 
principled approaches to variable importance are difficult 
because many metabolites cannot be identified [22]. 
Machine learning algorithms such as Random Forest 
(RF: [23]) can be used to identify potentially informative 
variables in such datasets [24]. RF is well suited to high 
dimensional datasets for several reasons; RF is non-
parametric, difficult to over-train, robust to outliers, 
provides information on variable importance and also 
provides built-in cross-validation [25]. These properties 
make RF a useful choice for metabolite prioritization in 
untargeted metabolomic studies. Another layer of support 
can be added by providing evidence of an ‘expected’ 
biological context. We believe this represents a pragmatic 
approach to analysis of a high-dimensional dataset where 
variable selection by physiological consideration would 
fail (because many metabolites cannot be identified), 
assumptions (e.g. independence of metabolites) for 
approaches like ANOVA are likely violated and 
traditional statistical power is difficult to achieve or even 
define due to high-dimensionality of the data. 
 
Here we use the approach outlined above. First we use 
the RF algorithm to screen an untargeted metabolomics 
dataset and identify metabolites potentially informing on 
chronological ageing in muscle tissue. Then we used the 
PIUMet software which implements the prize-collecting 
Steiner Forest algorithm to identify putative metabolic 
networks containing these metabolites which may be 
perturbed in older muscle and assess the biological 
context of the network members. 
 
RESULTS 
 
Random forest selection of metabolite features of 
predictive importance that stratify human muscle 
ageing 
 
The impact of metabolite selection using RF is seen in 
Figure 1. Prior to application of RF there is a similar 
level of variability in samples across the age groups, and 
no distinct clustering of the groups (Figure 1A). After 
application of RF we were able to identify metabolites 
that can separate the full cohort age class (Figure 1B, 
1C), and plotting principle components demonstrates a 
gradient effect across age groups in PC1 (old to young 
over PC1) (Figure 1D). This is the pattern we would 
expect to see if these metabolites are informative on age 
across the age-span of the study. The arrows in Figure 
1D show loadings which represent the weight of the 
labelled variables in the direction of older age. Thus RF 
was able to select potentially informative metabolites for 
further analysis. Figure 1E shows representative 
boxplots for potentially informative metabolite levels in 
the polar positive modality. The abundance of each 
metabolite across the classes reflects the direction of the 
arrows in the biplot (see Figure 1D) highlighting the 
potential differences between age groups for these 
metabolite features. Clear differences observed between 
metabolite abundance for each age group. Although not 
our primary objective we also examined the ability of 
RF to classify subjects according to age group. RF 
performed well when predicting older age (OOB error 
for old between 0% (RP neg) and 11% (HILIC Pos)) 
when using the young as a reference group, due to 
younger age being harder to classify using RF (OOB 
ranging from 50-100% for young) 
 
Annotation and identification of selected age 
predictive metabolite features 
 
Of the 42 metabolites selected via RF (10 per polarity 
and modality, except RP Pos which provided 12 due to 
equal importance scores), putative ID’s were found for 
31 using the PIUMet algorithm. Due to the difficulty 
associated with metabolite annotation in untargeted 
metabolomics [26], it was not possible to uniquely 
identify all metabolite features within a given mass 
tolerance (5ppm; see Supplementary Table 1 for full list 
of ID matches). 
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A number of metabolite matches provide plausible, biologically informed support for our approach and 
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Figure 1. (A) Pre RF PCA plot showing overlap of age groups and no defined clusters of metabolites predictive of age group for polar positive 
data. (B) Example variable importance and (C) multi-way importance plots generated from RF for polar positive data and the use of the 
randomForestExplainer R package. The most important predictive metabolites are selected out via Gini index and the top 10 (although 
arbitrary, this is generally selected as to where the variable importance falls off, i.e. as shown in the plot of panel B) selected for each polarity 
and ion mode to go forward for further analyses. (D) Post RF PCA plot for polar positive data, reduction of data to those metabolites most 
predictive of age shows clustering of age groups with most variability between age groups contained in PC1, with the direction and degree of 
correlation between each metabolite driving this difference shown through the loadings. (E) Representative boxplots for RF selected 
metabolites showing differences in metabolite abundance across age groups for these variables. 
 
provide confidence for the use of RF in selecting 
metabolites important for informing on processes 
associated with aging. For example, metabolite 2423 (MS 
predicted mw: 370.18135) (Figure 2A) matched a 
number of metabolites including Androsterone Sulfate 
and 5a-Dihydrotestosterone Sulfate, while metabolite 
2104 (MS predicted mw: 368.16575) (Figure 2B) 
matched to metabolites including Epitestosterone Sulfate, 
Dehydroepiandrosterone Sulfate and Testosterone 
Sulfate, which all relate to androgen steroid metabolism. 
It is well established that androgens such as testosterone 
decline with age in both men and women, and that this is 
associated with both declines in muscle mass and 
function [27]. Therefore, it may be expected that 
alterations in testosterone metabolism would be 
indicative of muscle ageing, and through the close 
association of testosterone levels with muscle mass, 
androgen metabolites could be predictive of human 
muscle ageing. Metabolite abundance in skeletal muscle 
for these two androgen related metabolites show declines 
across the age groups, which is line with previous 
literature ([28]: Figure 2A, 2B) 
A number of other groups were identified by PIUMet 
from the metabolites predictive of age, including lipid-
based metabolites (Lysophospholipids, itaconic acid, 
capryloylglycine), amines (spermine, histamine), amino 
acid metabolites (histamine, imadazolone-5-propionic 
acid) and energy metabolites (Phosphocreatine). All of 
these increased in abundance with age. 
 
Ageing-muscle metabolome networks 
 
After metabolite identification (Supplementary Table 1), 
the PIUMet algorithm generates a metabolite network 
using the prize-collecting Steiner Forest algorithm, and 
identifies a subset of metabolites most likely to 
correspond to the matching metabolite feature, providing 
a robustness score for each in relation to the network 
parameters (see Pirhaji et al. [29] for more details). 
Using this method, we generated a metabolite network 
associated with human muscle ageing (Figure 3). This 
network highlights proposed links between identified 
metabolites including potential protein-metabolite and 
protein-protein interactions. Notably, subnetworks 
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Figure 2. Representative boxplots of metabolite abundance for metabolites A) 2423 and B) 2104 which were selected via RF 
to be predictive of muscle age and were matched to a number of steroid and androgen metabolites following annotation 
using the PIUMet algorithm. Relative abundance for both metabolite features shows decline with age, a well-established relationship 
observed in ageing muscle for steroid and androgen metabolites. 
 
 
 
Figure 3. Metabolite network built through PIUMet. Key metabolite subnetworks centered around histamine, androgen and 
phospholipid metabolism, and phosphocreatine are highlighted as hubs for this ageing network. 
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were generated around physiologically relevant hubs 
such as phosphocreatine, androgen metabolism, 
histamine and lysophospholipid metabolism (see  
Figure 3). These data indicate a potential role for these 
metabolites, or the subnetworks involved with these 
metabolites, in human muscle ageing. 
 
DISCUSSION 
 
In the present study we used the RF algorithm to 
prioritise metabolites informative for age group from a 
large dataset of several thousand metabolites. We then 
used the PIUMet algorithm to identify metabolites and 
generate a metabolite network structure that reflected the 
known biology of human ageing and effects on muscle. 
This network included age associated metabolites such 
as phosphocreatine, androgens, amines/amino acids 
(histamine, histidine) and lipid metabolites as well as 
novel ageing related markers such as dihydrothymine, a 
marker of DNA damage and imidazolone-5-proprionic 
acid. 
 
Changes in Androgen metabolism were apparent  
in the ageing muscle metabolite signature, with the 
metabolites dehydroepiandrosterone sulfate and 5-alpha-
dihydrotestosterone sulfate showing declines in 
abundance with increasing age (see Figure 2A, 2B). The 
association between testosterone and ageing is long 
established; both total and free testosterone decline with 
age in men and women [29]. Moreover, age-related 
declines in testosterone have been linked to reduced 
muscle mass and strength [30], immobility, physical 
performance [31], and frailty [27]. Further substantiating 
our findings, in a recent untargeted metabolomics study, 
it was demonstrated that chronological age was 
significantly correlated with the steroid/androgen 
metabolites 4-androsten-3beta, 17beta-dioldmonosulfate 
and 4-androsten-3beta, 17beta-diol disulfate 2 [32]. The 
present findings therefore provide good confidence that 
our RF based bioinformatics workflow is able to yield 
useful information about the metabolomic signature of 
ageing skeletal muscle. 
 
The lipid composition of the muscle cell influences 
membrane structure, function, permeability, molecular 
transport, intracellular signalling [33] and the 
synthesis of steroid hormones including the androgens 
[34]. This may explain the link between lipid-based 
metabolites and androgens in our PIUMet predicted 
network. With ageing, the composition of lipids shifts 
towards saturated intramyocellular lipids [35, 36] 
which when coupled to declines in mitochondrial 
content [37], can lead to insulin resistance [38]. In 
support of these changes to lipid composition with age, 
we report that a number of lipid compounds were 
identified in our bioinformatic analysis and changed 
with age; namely the Lysophospholipids (LysoPE(0:0/ 
22:6)/(22:6/0:0), LysoPE(0:0/20:5)/(20:5/0:0), LysoPE 
(0:0/24:6) and LysoPC(0:0/18:0), the branched fatty 
acid Itaconic Acid and the medium chain acylglycine 
Capryloylglycine. The lysophospholipids are produced 
via the breakdown of membrane phospholipids [39]. 
The apparent functional relationship between increases 
in lysophophospholipids in the present study and 
breakdown of cellular membranes may have links to 
musculoskeletal ageing e.g. with a decrease in muscle 
mitochondrial phosphatidylethanolamine being observed 
in ageing mice [40]. This decline in mitochondrial 
phosphatidylethanolamine may be implicit in the declines 
in mitochondrial function observed with ageing [41], and 
associated functional decline in muscle. Further, the 
lysophospholipids have important intracellular signalling 
roles regulating processes as diverse as blood pressure 
regulation, cell proliferation, cell survival and cell 
morphology [42, 43]; in particular lysophosphatidic  
acid (LysoPA) and lysophosphatidylcholine (LysoPC). 
Recent findings have also linked the levels of LysoPC in 
plasma to chronological ageing [44], which we now add 
support to, albeit in muscle, within the present study i.e. 
increased levels in both of the LysoPC and LysoPE 
species. Such changes in abundance of these compounds 
may contribute to age-associated muscle decline and 
require follow-up. 
 
Itaconic acid or Itaconate is a small branched-chain 
fatty acid, originally identified as compound produced 
by the fungus Aspergillus [45]. Recently this compound 
has been found to be produced by macrophages [46] 
linked to the M1 polarization phase of the macrophage 
response to pro-inflammatory signals in order to remove 
foreign and damaged cells [47]. This M1 polarization 
leads to impairments to the flux through the TCA cycle, 
with Itaconic acid being formed by the decarboxylation 
of the TCA intermediate cis-acotinate through the 
enzyme immune-responsive gene (Irg1; [48]). Itaconate 
can then act as an antimicrobial agent by disrupting the 
glyoxylate cycle used by pathogens [47, 49]. Ageing 
has long been associated with inflammation, and 
associated declines in skeletal muscle mass and function 
[50], as well as impaired immune responsiveness [51, 
52]. Therefore, increases in itaconate with age, may 
relate to an increased inflammatory immune response; 
indeed, there is evidence in rats that itaconate is capable 
of reducing levels of visceral fat through the inhibition 
of F6P2Kinase [45], potentially responding on two 
fronts to the ageing inflammatory response. 
 
Capryloylglycine or n-octanoylglycine is a medium 
chain fatty acid. It is produced as a result of acylCoA 
esters conjugating with glycine through the enzyme 
glycine N-acyltransferase [53], and is normally observed 
in urine as a marker of in-born errors of metabolism such 
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as medium chain acyl CoA dehydrogenase deficiency 
(MCADD; [54]). The process leading to the increase in 
capryloylglycine with age in the present study is unclear. 
Yet, with its role in regulation of acylCoA levels, it may 
relate to impaired mitochondrial function or content with 
age. With many of the lipid metabolites identified 
providing the potential for impairment to energetic 
pathways, particularly involving the mitochondria and 
oxidative phosphorylation, it may be expected that other 
aspects of energy metabolism are perturbed in ageing 
muscle. In support of this thesis Phosphocreatine was 
also identified as a key metabolite in ageing muscle  
in the present findings, with the PIUMet predictive 
network linking it to both Itaconic acid and LysoPE (see 
Figure 3) 
 
The polyamines; Spermine and Spermidine have been 
compounds of continued interest in ageing and health 
research in recent years [55]. At a systems level they are 
considered essential growth factors for cells, being 
involved in multiple processes from signal transduction 
to protein and DNA synthesis, and have key roles in the 
regulation of skeletal muscle mass [56]. Here we found 
spermine to be predictive of age, with increased 
abundance with age (not significant following FDR 
correction), which supports previous muscle metabolome 
data looking at differences between old and young 
cohorts [17]. Reduced expression of spermine oxidase 
(SMOX), leading to increased spermine levels, has been 
shown to be linked with muscle atrophy in mouse models 
[57]. Concomitantly overexpression of SMOX in C2C12 
murine myotubes increases overall fibre size [58]. 
Moreover, in a number of neuromuscular disorders, an 
increased concentration of the polyamines and associated 
metabolites is often observed [59, 60], highlighting their 
vital role in the skeletal muscle mass regulation, and 
indicating that they might be related to impaired 
regulation of muscle mass with ageing. 
 
The synthesis and degradation of polyamines is closely 
linked to the metabolism of another amine identified 
within our metabolite signature of muscle ageing - 
histamine. The interplay between the two amine 
pathways is still not fully understood, however  
histamine may impact expression of the enzyme ornithine 
decarboxylase (ODC), a key step in polyamine synthesis 
[61–63]. Histamine is a prominent vasoactive substance, 
helping regulate blood-flow and vascular tone [64, 65]. It 
is well established that the control of blood flow is 
impaired in ageing with significant decrease in flow and 
microvascular perfusion to the muscle in response to 
nutritive stimuli [66, 67]. Though speculative, increased 
levels of histamine observed in older muscle could 
represent a compensatory mechanism. Interestingly, links 
between amines, polyamines and androgens exist, hence 
the predicted links between these compounds in  
the PIUMet network analyses (Figure 3). For instance, 
treatment of orchidectomized male mice with 
testosterone led to increased expression of ODC, 
regulating polyamine synthesis and degradation [68, 69]. 
Furthermore androgen receptor knockout leads to the 
down regulation in expression of ODC and other 
enzymatic proteins, in muscle, involved in polyamine 
biosynthesis [56]. These interlinked pathways could be 
implicit in the regulation of skeletal muscle mass with 
ageing and could provide useful therapeutic targets for 
future investigation. 
 
In addition to those metabolites which formed the major 
hubs and subnetworks for the present ageing muscle 
signature, there were a small number of other minor 
metabolites which were also shown to be powerful in age 
prediction, namely imadozolone-5-proprionic acid, 
dihydrothymine, 1,7/3,7 dimethyluric acid, aniline and 
tagatose. Imadozolone-5-proprionic acid is a metabolite 
of histidine closely linked to histamine within the 
predicted network via histidine and the enzyme histidine 
decarboxylase, which catalyses the decarboxylation of 
histidine to histamine [70]. Dihydrothymine is a 
breakdown product of the nucleotide thymine, however it 
is also believed to represent the presence of potential 
DNA damage [71]. The idea that DNA damage may be a 
contributing factor towards cellular ageing has long been 
proposed [72, 73], and therefore could indicate the 
presence of DNA damage in ageing muscle. 1,7/3,7-
dimethylurate is another metabolite of nucleotide 
metabolism associated with the purine xanthine. It is also 
known as a breakdown product and marker of the 
pharmacokinetics of the COPD and asthma drug 
Theophylline or Dimethylxanthine [74], and in the 
metabolism of caffeine [75]. Interestingly the isomer 1,7 
dimethylurate in plasma has been shown to be related to 
chronological ageing in previous untargeted meta-
bolomics studies [32]. This provides support for this 
compound as a potentially novel marker, with more 
research needed into its potential biological actions and 
putative links to ageing. Both aniline and tagatose were 
putatively identified within these samples. Tagatose is 
common in sweeteners in food and dairy products and 
therefore may be reflective of dietary differences, 
whereas aniline is an industrial chemical not expected to 
be present endogenously and therefore may reflect a 
contaminant or an inaccurately identified compound. 
 
This work is primarily exploratory in nature and is not 
intended to define a definitive metabolic signature of 
ageing and health. It is more an attempt to generate leads 
and hypotheses to investigate in future, i.e. through 
identification of metabolites and/or metabolic pathways 
for manipulation via pharmaceutical and drug targets in 
models of ageing and disease using a more targeted 
approach, and to assist in confirming a potential ageing 
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metabolite signature and associated therapeutic 
intervention for health across the lifespan. Moreover, it 
is also important to consider the aspect of gender in the 
context of future work, whilst not possible in the current 
study, there is clear evidence of sexual dimorphism in 
the context of skeletal muscle aging [76]. It is therefore 
possible that metabolite signatures may show distinct 
gender specific differences particularly in those 
associated with androgen metabolism. In addition to this, 
the sample size could be considered somewhat limited in 
the current study when it comes to OMICs, and therefore 
statistical power could be compromised in this type of 
analyses. However, the use of RF is optimal for dealing 
with so called “small n large p” data sets [77] by 
minimising the potential for overfitting data. However, 
follow up work with a larger cohort is clearly needed to 
independently validate our findings. A current major 
problem in the field of metabolomics, are the issues 
involved with metabolite feature annotation and 
accuracy of ID in untargeted metabolomics [26]. Despite 
significant progress in recent years, annotation is still 
lagging far behind the other OMICs approaches such as 
proteomics and genomics/transcriptomics. 
 
The present study reveals that a novel bioinformatics-
based metabolomics approach involving the use of both 
Random Forest to detect metabolites important to predict 
age and PIUMet to fit these to predicted metabolic 
networks, is a potentially useful tool to classify human 
tissue ageing. This process provides a pragmatic 
approach to datasets such as those seen in untargeted 
metabolomics where many potentially biologically 
informative entities cannot be identified, and false 
positive rates are potentially very high. Based on the 
work presented here, future untargeted work through 
recruitment of a second independent cohort would be 
needed to validate this approach and the identification of 
the potential age important metabolites presented here, 
this could then be followed by a more robust targeted 
validation in a third independent cohort. Once fully 
validated this approach could be utilised in future studies 
to investigate the links between age predictive 
metabolites and common biomarkers linked to health and 
disease across our ageing population, and therefore could 
be used to assist towards the identification of novel 
preventative measures for age associated diseases. 
 
MATERIALS AND METHODS 
 
Subject recruitment, ethics and study data collection 
 
This work utilises samples collected as part of previously 
published work [78]. This study was reviewed and 
approved by the University of Nottingham Medical 
School Ethics Committee (D/2/2006) and was performed 
in accordance with the Declaration of Helsinki. All 
subjects gave written informed consent to participate in 
the study prior to inclusion after all procedures and risks 
were explained. 
 
Three groups of subjects consisting of young (n = 10, 25 
± 4 yr; BMI 24 ± 1 kg/m2), middle-aged (n = 18, 50 ± 4 
yr; BMI 27 ± 1 kg/m2), and older (n = 18, 70 ± 3 yr; 
BMI 27 ± 1 kg/m2) men and women (~50:50) who were 
well matched for baseline lean mass, were recruited (see 
Table 1 for summary of subject characteristics). All 
subjects were screened by means of a medical 
questionnaire, physical examination, and resting ECG, 
with exclusions for moderate muscle wasting (>1 SD 
below age norms); metabolic, respiratory, or cardio-
vascular disorders; or other signs and symptoms of ill 
health. Once enrolled in the study, volunteers were 
instructed to refrain from exercise for 72 hours and 
return to the laboratories for testing in an overnight 
fasted state. Upon arrival, body composition was 
measured using dual-energy X-ray absorptiometry. 
Volunteers then provided a venous blood sample for the 
measurement of fasting insulin, glucose, cholesterol and 
triglycerides, followed by measurements of resting heart 
rate (RHR) and mean arterial pressure (MAP). Muscle 
biopsies of the m. vastus lateralis were then taken under 
sterile conditions using the conchotome biopsy 
technique [79], with 1% lidocaine (B. Braun Melsungen) 
as local anaesthetic. Muscle was rapidly dissected free of 
fat and connective tissue, washed in ice-cold saline, and 
snap frozen in liquid N2 before storage at –80°C until 
further analysis. 
 
Untargeted metabolomic analysis 
 
Sample preparation 
Approximately 30 mg of muscle tissue was mixed with 
1000 µL of methanol:water:chloroform (2.5:1:1 [v/v/v]) 
and homogenised in a Qiagen TissueLyser II (Qiagen, 
Germany) at 30 Hz for 2 × 30 s cycle followed by 
shaking at room temperature for 10 min. Samples were 
centrifuged (10,000 g, 3 °C, 5 min) followed by transfer 
of ~1000 µL of the supernatant to a clean 2 mL 
microcentrifuge tube. 500 µL of HPLC grade water was 
added followed by vortex mixing and centrifugation 
(10,000 g, 3 °C, 5 min) to induce phase separation. The 
upper polar phase (methanol/water) and the lower non-
polar phase (chloroform) were transferred in to separate 
clean 2 mL autosampler vials and dried under nitrogen. 
Samples were stored at −80 °C until analysis. 
 
UHPLC-MS 
All samples were analysed as described previously [80] 
using an UltiMate U3000 RSLC UHPLC system coupled 
to an electrospray Q-Exactive mass spectrometer.  
The polar phase samples were analysed applying HILIC-
MS after being reconstituted in 100 μL of 95/5 
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Table 1. Summary of subject characteristics. All data as mean ± SEM. 
 Young Middle aged Old 
Leg (dominant) Lean Mass (g) 8510.1 ± 508.3 7975.4 ± 487.9 8160.5 ± 523.3 
Whole Body Strength (N) 4404.7 ± 308.4 4182.3 ± 357 3570.6 ± 188.7 
% Body Fat 28.1 ± 4.0 34.5 ± 1.6 32.8 ± 0.2 
Fasting Insulin (μU/ml) 4.5 ± 0.6 4 ± 0.4 4.9 ± 0.5 
Fasting Glucose (mM) 5.1 ± 0.1 5.5 ± 0.2 5.8 ± 0.1 
HDL Cholesterol (mM) 1.2 ± 0.1 1.4 ± 0.1 1.2 ± 0.1 
LDL Cholesterol (mM) 2.4 ± 0.5 3.1 ± 0.3 3.2 ± 0.2 
Triglycerides (mM) 0.9 ± 0.1 1.0 ± 0.1 1.1 ± 0.1 
 
acetonitrile/water, and the non-polar phase samples were 
analysed applying reversed phase C18-MS after being 
reconstituted in 100 μL of 50/50 water/methanol. After 
reconstitution, 20 µL of each sample was pooled in to a 
QC sample to quantify technical reproducibility. For 
HILIC MS, an Accucore 150-Amide HILIC UHPLC 
column (100 mm × 2.1 mm 2.6 µm, Thermo-Fisher Ltd., 
UK) was used with mobile phase A: 95% acetonitrile and 
5 mM Ammonium Formate (pH 3), and mobile phase B: 
5 mM Ammonium Formate in water at (pH 3). For 
reversed phase MS a Hypersil Gold UHPLC C18 column 
(100 mm × 2.1 mm 1.9 µm, Thermo-Fisher Ltd.) was 
used with mobile phase A: water with 0.1% formic acid, 
and mobile phase B: methanol with 0.1% formic acid. 
5µL of each sample was injected and analysed applying 
positive-negative ion mode switching with data collected 
in the m/z range 100–1000. Ten QC samples were 
analysed at the start of the analysis followed by a QC 
sample after every 6th biological sample and two QC 
samples at the end of the analytical run. Biological 
samples were randomised across the analytical batch. 
Gradient elution profiles and mass spectrometer 
conditions used for each mode are provided in Table 2. 
 
Sample pre-processing 
Raw data (.RAW) files were pre-processed using vendor 
software Compound Discoverer (Thermo Scientific, 
Bremen, Germany; mass tolerance: 5ppm, Signal/Noise: 
3, min number of isotopes: 1) to extract out metabolite 
features and corresponding accurate mass molecular 
weight. Data were exported as a data matrix of metabolite 
feature (molecular weight-retention time pair) vs. sample 
with associated chromatographic peak areas for a 
detected metabolite for each polarity (Polar/Non Polar) 
and ion mode (Positive and Negative). Each metabolite 
feature with a relative standard deviation calculated for 
QC samples greater than 20% and not detected in greater 
than 70% of QC samples were removed prior to further 
downstream data analysis. This is a commonly applied 
technique for untargeted metabolomics [81] that has been 
recommended in recent guidelines [82]. In total, 5655 
metabolite features were detected in the muscle samples; 
2819 polar positive, 1251 polar negative, 1239 non-polar 
positive and 346 non-polar negative. 
 
Statistics 
 
Data for each polarity and ion mode was analysed 
separately utilising in-house R (R Core Team 2013) 
scripts. Prior to analysis, and to account for any 
differences in the amount of muscle processed for each 
sample (exactly 30mg was not possible for some samples 
due to low sample amount), SUM normalisation of 
metabolite abundances was performed [83, 84]. 
 
Random forest selection of metabolite features of 
predictive importance 
The Random Forest (RF) algorithm was used to identify 
metabolites informative on age class [23]. Intuitively 
high correlation between predictor features (ill 
conditioning) means that many features provide the 
same/similar information. Consequently estimates of e.g. 
feature importance are diluted. Toloşi and Lengauer 
explored this issue in RF and other feature selection 
methods concluding that even very relevant features can 
be assigned small importance measures if they are highly 
correlated with many other features [85]. Due to the 
exploratory nature of our study we took a pragmatic 
approach and removed highly correlated features 
(Pearson correlation ≥ 0.9) before applying RF. Features 
were ranked by the Gini coefficient, a measure of 
terminal leaf purity for RF trees. With limited numbers 
of subjects in each group, RF variable selection was 
performed only on the extremes of age, i.e. old versus 
young with the expectation that middle aged would fall 
between these two. 
 
The top 10 most important metabolite features by Gini 
coefficient from each polarity and ion mode were 
selected and a reduced data set based on these 
metabolites was subjected to further analyses. Lists of 
polar and non-polar metabolites were generated alongside 
their respective molecular weights, m/z values and 
predicted chemical formulae following referencing back  
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Table 2A. UHPLC gradient elution profiles for each polarity. 
HILIC Phase 
Time (mins) 
% Buffer Composition 
Buffer A - 
Acetonitrile:Water (95:5) 
with 5mM Ammonium 
Formate (pH 3) 
Buffer B - 
Water:Acetonitrile (95:5) 
with 5mM Ammonium 
Formate (pH 3) 
0 95 5 
1 95 5 
12 55 45 
15 55 45 
16 95 5 
21 95 5 
Reversed Phase (C18) 
Time (mins) 
% Buffer Composition 
Buffer A - Water with 
0.1% Formic Acid 
Buffer B - Methanol with 
0.1% Formic Acid 
0 95 5 
2 95 5 
9 5 95 
12 5 95 
13 95 5 
16 95 5 
 
Table 2B. MS operating conditions for each ion mode. 
MS Conditions - Q-Exactive MS 
Spray Voltage (kV) 3.5 (ESI-)/4.5 (ESI+) 
Sheath Gas (AU) 40 
Aux Gas (AU) 15 
Sweep Gas (AU) 0 
S-Lens 100 
Resolution 35,000 (FWHM, m/z 200) 
Capillary Temp (°C) 300 
ESI Heater Temp (°C) 300 
 
to pre-processing through Compound Discoverer. For 
each metabolite feature univariate analyses was 
performed to detect differences in relative metabolite 
abundance between old and young using the univariate 
function (Mann-Whitney U Test) provided in the muma 
R package [86] and negative log10 of the Benjamini-
Hochberg corrected p-values were obtained. 
 
Metabolite annotation, identification and predicted 
integrated metabolite network analyses 
Lists of metabolite features (identified by their m/z 
value and polarity) and the results of the univariate test 
used to determine differences between samples were 
input into the PIUMet algorithm [87]. PIUMet uses  
this information and implements a machine learning 
approach to infer pathways and experimentally 
undetected components from the list of untargeted 
metabolite features provided, by utilising an integrative 
network of over one million protein and metabolite 
interactions, obtained from the iRefIndex, HMDB and 
Recon 2 databases (see [87] for more detailed 
information on PIUMet). Application of PIUMet allow-
ed us to obtain putative metabolite IDs and generate 
potential molecular/metabolite networks which may be 
important in the muscle ageing phenotype. The network 
data was extracted from the PIUMet edge frequency file 
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and the PIUMet network reconstituted in Cytoscape 3.7 
[88] for legibility.
Abbreviations 
ANOVA: analysis of variance; BMI: Body Mass Index; 
COPD: Chronic Obstructive Pulmonary Disease; ECG: 
Electrocardiogram; HILIC-MS: Hydrophilic interaction 
liquid chromatography mass spectrometry; HMDB: 
Human metabolome database; HPLC: High performance 
liquid chromatography; MAP: Mean arterial pressure; 
RF: Random Forest; RHR: Resting heart rate; UHPLC: 
Ultra high performance liquid chromatography. 
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Supplementary Table 1. Putative metabolite IDs for age important metabolites identified by RF. 
